Zai Lab Limited Stock Price, News & Analysis

Blueprint Medicines and Zai Lab have entered into an exclusive collaboration to develop BLU-945 and BLU-701 for EGFR-driven non-small cell lung cancer (NSCLC) in Greater China. This partnership aims to leverage Blueprint's innovation in precision therapies and Zai Lab's oncology expertise to address the significant medical needs in the region, where a high percentage of NSCLC patients have EGFR mutations. Blueprint will receive an upfront payment of $25 million and potential milestones totaling $590 million, with Zai Lab managing development costs.

Zai Lab has secured exclusive rights to develop and commercialize KarXT (xanomeline-trospium) in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. The agreement entails an upfront payment of $35 million to Karuna Therapeutics and potential milestone payments up to $152 million. Zai Lab will undertake the development and commercialization efforts, with tiered royalties on net sales. KarXT targets psychiatric conditions, showing promising results in late-stage trials for schizophrenia and Alzheimer's-related psychosis.

Zai Lab has secured exclusive rights to develop and commercialize KarXT in Greater China through a new collaboration with Karuna Therapeutics. The agreement includes a $35 million upfront payment and potential milestones totaling up to $152 million, along with royalties based on sales. KarXT is an investigational treatment for psychiatric conditions, showing significant efficacy in clinical trials. The partnership aims to address the substantial need for effective therapies in schizophrenia and dementia-related psychosis in the region.

Zai Lab has secured exclusive rights to develop and commercialize KarXT in Greater China, with a total deal value exceeding $267 million. Karuna Therapeutics will receive an upfront payment of $35 million along with potential milestone payments of up to $152 million and tiered royalties. KarXT has shown promising results in treating schizophrenia and Alzheimer’s-related psychosis, with ongoing late-stage trials. Zai Lab will oversee development and commercialization efforts in the region.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a global biopharmaceutical company, announced participation in several upcoming virtual investor conferences in November 2021. They will present at the Goldman Sachs Asia Pacific Healthcare Forum on November 15, the BioCentury-BayHelix China Healthcare Summit from November 16-19, and the Jefferies London Healthcare Conference with a presentation available starting November 18. Investors can access webcasts and replays through Zai Lab's website.

Zai Lab Limited (NASDAQ: ZLAB) announced that it will release its financial results for Q3 2021 on November 9, 2021, after U.S. markets close. A conference call and webcast is scheduled for November 10, 2021, at 8:00 a.m. ET. This biopharmaceutical company focuses on innovative therapies in oncology, autoimmune disorders, and infectious diseases, with a commitment to addressing unmet medical needs. Investors can access the conference call through their website after registering in advance.

Zai Lab has initiated patient enrollment in a pivotal global Phase 2 trial of odronextamab monotherapy for B-cell non-Hodgkin lymphoma (B-NHL) in China. This study, conducted in collaboration with Regeneron, aims to assess treatment efficacy across various B-NHL subtypes, including follicular and diffuse large B-cell lymphoma. The trial's primary goal is to evaluate the anti-tumor activity based on objective response rates. With an annual incidence of 92,834 NHL cases in China, this study represents a significant opportunity to address unmet medical needs in a heavily affected patient population.

Zai Lab has announced positive results from a Phase 1b proof-of-concept study of ZL-1102, an anti-IL-17A Humabody® for chronic plaque psoriasis. This study is the first to show clinical improvement through psoriatic skin penetration and involved 53 patients, reporting improvements in PASI scores, erythema, and scaling. The safety profile was similar to placebo. The successful trial triggers a milestone payment to Crescendo Biologics, which licenses ZL-1102 to Zai Lab, marking a significant advancement in their collaboration for developing targeted therapies.

Zai Lab Limited (NASDAQ: ZLAB) announced positive topline results from a Phase 1b proof-of-concept study of ZL-1102, a topical treatment for mild-to-moderate chronic plaque psoriasis. The study showed a 45% relative improvement in the local Psoriasis Area Severity Index (PASI) score after four weeks, with sustained clinical benefits up to six weeks post-treatment. The drug demonstrated a favorable safety profile compared to placebo, with minimal adverse events. Zai Lab plans to advance ZL-1102 into full development, including registrational studies, aiming to address the significant need for effective topical treatments for psoriasis.